X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NT-300 is an oral, broad-spectrum antiviral drug designed to provide antiviral concentrations of drug to the respiratory tract throughout twice-daily dosing.
Lead Product(s): Nitazoxanide
Therapeutic Area: Infections and Infectious Diseases Product Name: NT-300
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021
Details:
The Phase 3 clinical trial aims to evaluate safety and efficacy of Romark's investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19.
Lead Product(s): Nitazoxanide
Therapeutic Area: Infections and Infectious Diseases Product Name: NT-300
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
Clinical development program for NT-300 includes trials addressing prevention and treatment of COVID-19 and other viral respiratory illnesses.
Lead Product(s): Nitazoxanide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
